AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35300888 — intervention group
Group type: COMPARATOR
Intervention: Holmium: YAG (Ho:YAG)
Number of subjects: 120
Study 33479775 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive 1000 mg aspirin
Number of subjects: 360
Study 33479775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 32598248 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer-188 (0.94%), chitosan (2.38%), swelling time (1.81 h), parts of chitosan (78.51%)
Number of subjects: 8
Study 32598248 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan and Poloxamer-188 concentrations
Number of subjects: 8
Study 32598248 — intervention group
Group type: EXPERIMENTAL
Intervention: In-silico screening methodology
Number of subjects: 8
Study 32598248 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical fitting and analysis
Number of subjects: 8
Study 32598248 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-polymer interaction study
Number of subjects: 8
Study 34262711 — intervention group
Group type: EXPERIMENTAL
Intervention: Food ration bars enriched with arginine (2 g/day), ß‐alanine (2 g/day), and Nigella sativa (2 g/day)
Number of subjects: 54
Study 34262711 — intervention group
Group type: COMPARATOR
Intervention: Nonenriched food ration bars
Number of subjects: 54
Study 32367114 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine + antidepressant
Number of subjects: 0
Study 32367114 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant + placebo
Number of subjects: 0
Study 34569129 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation for 6 weeks
Number of subjects: 72
Study 34569129 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 32966685 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate diet-induced weight loss
Number of subjects: 0
Study 32966685 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight participants
Number of subjects: 0
Study 32966685 — intervention group
Group type: COMPARATOR
Intervention: Obese participants before weight loss
Number of subjects: 0
Study 32966685 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants after weight loss
Number of subjects: 0
Study 33276689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 75
Study 33276689 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hydroxynevirapine
Number of subjects: 75
Study 33276689 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxynevirapine
Number of subjects: 75
Study 33921327 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based care prevention, functional training exercise program
Number of subjects: 1509
Study 35476942 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT, 30 Gy/3 fx)
Number of subjects: 24
Study 35476942 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole pelvic radiotherapy (WPRT, 45 Gy/25 fx + SIB boost to 65 Gy)
Number of subjects: 24
Study 35476942 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 24
Study 35476942 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole pelvic radiotherapy (WPRT)
Number of subjects: 24
Study 36191080 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3732394 (10 mg starting dose, single ascending doses)
Number of subjects: 18
Study 36191080 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3732394 (maximum dose 80 mg)
Number of subjects: 18
Study 36191080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 33727632 — intervention group
Group type: COMPARATOR
Intervention: 150 min/week (low-volume) aerobic exercise
Number of subjects: 720
Study 33727632 — intervention group
Group type: COMPARATOR
Intervention: 225 min/week (mid-volume) aerobic exercise
Number of subjects: 720
Study 33727632 — intervention group
Group type: COMPARATOR
Intervention: 300 min/week (high-volume) aerobic exercise
Number of subjects: 720
Study 34389168 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDT group)
Number of subjects: 312
Study 34389168 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous fluid therapy (STD group)
Number of subjects: 312
Study 33216664 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-minimized powered wheelchair skills training program (Co-pilot) - 6 sessions
Number of subjects: 25
Study 33216664 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-minimized powered wheelchair skills training program (Co-pilot) - 12 sessions
Number of subjects: 25
Study 33216664 — intervention group
Group type: COMPARATOR
Intervention: Control intervention - 6 sessions
Number of subjects: 25
Study 33216664 — intervention group
Group type: COMPARATOR
Intervention: Control intervention - 12 sessions
Number of subjects: 25
Study 33216664 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-minimized powered wheelchair skills training program (Co-pilot)
Number of subjects: 25
Study 35190827 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive education
Number of subjects: 140
Study 35190827 — intervention group
Group type: COMPARATOR
Intervention: Didactic education (control)
Number of subjects: 140
Study 33926423 — intervention group
Group type: EXPERIMENTAL
Intervention: Double combination of oral OADs (sulfonylurea and thiazolidinediones)
Number of subjects: 3355
Study 33926423 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of oral OADs (metformin, sulfonylurea, and thiazolidinediones)
Number of subjects: 3355
Study 32661909 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant 200 mg daily
Number of subjects: 140
Study 32661909 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant 500 mg daily
Number of subjects: 140
Study 32661909 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant (up to 1000 mg daily)
Number of subjects: 140
Study 32661909 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant (500 mg dose)
Number of subjects: 140
Study 32661909 — intervention group
Group type: EXPERIMENTAL
Intervention: Elacestrant (200 mg dose)
Number of subjects: 140
Study 32661909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 35042918 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular Metal (porous tantalum coating)
Number of subjects: 118
Study 35042918 — intervention group
Group type: COMPARATOR
Intervention: VerSys (fiber mesh coating)
Number of subjects: 118
Study 35042918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 118
Study 34772339 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia education
Number of subjects: 120
Study 34772339 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia education together with teach-back method
Number of subjects: 120
Study 34772339 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 32613433 — intervention group
Group type: EXPERIMENTAL
Intervention: A-PRF+
Number of subjects: 102
Study 32613433 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 102
Study 32613433 — intervention group
Group type: COMPARATOR
Intervention: Suture alone
Number of subjects: 102
Study 32759285 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-all group (elective freezing of all embryos) with gonadotropin releasing hormone agonist triggering and single frozen-thawed blastocyst transfer in a subsequent modified natural cycle.
Number of subjects: 460
Study 32759285 — intervention group
Group type: COMPARATOR
Intervention: Fresh transfer group with human chorionic gonadotropin triggering and single blastocyst transfer in the fresh cycle.
Number of subjects: 460
Study 32759285 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-all group
Number of subjects: 460
Study 32759285 — intervention group
Group type: COMPARATOR
Intervention: Fresh transfer group
Number of subjects: 460
Study 32759285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 460
Study 32223966 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IL‐1ra levels
Number of subjects: 0
Study 32223966 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IL‐6 levels (reduced bio-function)
Number of subjects: 0
Study 32223966 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1ra
Number of subjects: 0
Study 32223966 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6
Number of subjects: 0
Study 32223966 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐16
Number of subjects: 0
Study 35585787 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct lateral approach
Number of subjects: 150
Study 35585787 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral approach
Number of subjects: 150
Study 33038677 — intervention group
Group type: EXPERIMENTAL
Intervention: Rethink Vape Materials
Number of subjects: 268
Study 33038677 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study 33092401 — intervention group
Group type: EXPERIMENTAL
Intervention: MAVIG X-ray protective drape (MXPD)
Number of subjects: 632
Study 35598008 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride sustained-release tablets (0.5 g/day for the first 2 weeks, 1 g/day for the second 2 weeks, and 2 g/day for the remaining period if tolerated)
Number of subjects: 262
Study 35598008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical inert placebo)
Number of subjects: 262
Study 35598008 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride sustained-release tablets
Number of subjects: 262
Study 33607697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study 33607697 — intervention group
Group type: COMPARATOR
Intervention: No mindfulness training (control)
Number of subjects: 0
Study 36397220 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking combined with TEAS (Lieque [LU 7] and Zusanli [ST 36], continuous wave, 20 Hz, 1 mA, 30 min each time, once a day)
Number of subjects: 200
Study 36397220 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 200
Study 35182665 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi-Gan-san (YGS)
Number of subjects: 38
Study 35182665 — intervention group
Group type: COMPARATOR
Intervention: YGS placebo
Number of subjects: 38
Study 35291399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg/mL 20 mL plus dexmedetomidine 100 µg
Number of subjects: 42
Study 35291399 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 20 mL alone
Number of subjects: 42
Study 36126050 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based application for a specific 9‐week intervention in depression and type 1 diabetes
Number of subjects: 0
Study 36126050 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 0
Study 36329553 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein 120 mg daily for 12 months
Number of subjects: 24
Study 36329553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32034285 — intervention group
Group type: EXPERIMENTAL
Intervention: LEN-CR (lenalidomide maintenance until achievement of complete response)
Number of subjects: 502
Study 32034285 — intervention group
Group type: COMPARATOR
Intervention: LEN-2Y (lenalidomide maintenance for a fixed duration of 2 years)
Number of subjects: 502
Study 34679188 — intervention group
Group type: EXPERIMENTAL
Intervention: Libre del Cigarrillo (LDC) - 11 booklets and 9 pamphlets mailed monthly over 18 months
Number of subjects: 1417
Study 34679188 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) - a single Spanish‐language self‐help booklet from the National Cancer Institute
Number of subjects: 1417
Study 33358235 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate plus alfacalcidol
Number of subjects: 412
Study 33358235 — intervention group
Group type: COMPARATOR
Intervention: Alendronate alone
Number of subjects: 412
Study 32371690 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional nerve blockade (RNB)
Number of subjects: 32
Study 32371690 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration anesthesia
Number of subjects: 32
Study 35191716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral couple therapy (CBCT) for 12 weeks
Number of subjects: 108
Study 35191716 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine treatment for 12 weeks
Number of subjects: 108
Study 34295153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand holding with relatives (HR)
Number of subjects: 120
Study 34295153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand holding with strangers (HS)
Number of subjects: 120
Study 34295153 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 32470863 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG)
Number of subjects: 59
Study 32470863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 35731251 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin added to intradetrusor injections of BoNT A
Number of subjects: 49
Study 35731251 — intervention group
Group type: COMPARATOR
Intervention: Intradetrusor injections of BoNT A
Number of subjects: 49
Study 33048179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal neuromodulation combined with pudendal nerve release using the ENTRAMI technique
Number of subjects: 16
Study 32181236 — intervention group
Group type: EXPERIMENTAL
Intervention: Category 1 patients (strong genetic basis)
Number of subjects: 258399
Study 32181236 — intervention group
Group type: EXPERIMENTAL
Intervention: Category 2 patients (suspected genetic component)
Number of subjects: 258399
Study 32181236 — intervention group
Group type: COMPARATOR
Intervention: Category 3 patients (no genetic disease)
Number of subjects: 258399
Study 34368888 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills treatment (TX) workshops
Number of subjects: 128
Study 34368888 — intervention group
Group type: COMPARATOR
Intervention: Education control (EC) workshops
Number of subjects: 128
Study 34368888 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL)
Number of subjects: 128
Study 33691284 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT at Middle
Number of subjects: 16
Study 33691284 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT at End
Number of subjects: 16
Study 33691284 — intervention group
Group type: COMPARATOR
Intervention: HIIT at Beginning
Number of subjects: 16
Study 32877981 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (INF group)
Number of subjects: 80
Study 32877981 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX group)
Number of subjects: 80
Study 35179337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon angioplasty (MagicTouch, Concept Medical)
Number of subjects: 6
Study 35179337 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon angioplasty (Ranger, Boston Scientific)
Number of subjects: 6
Study 34461961 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 ?g/day) for 16 weeks, continuing to 24 weeks if fracture remains unhealed
Number of subjects: 136
Study 34461961 — intervention group
Group type: COMPARATOR
Intervention: Usual Army standard care
Number of subjects: 136
Study 33030269 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mL blood donation
Number of subjects: 21
Study 33030269 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mL blood donation
Number of subjects: 21
Study 33030269 — intervention group
Group type: COMPARATOR
Intervention: Sham donation of 900 mL
Number of subjects: 21
Study 33030269 — intervention group
Group type: COMPARATOR
Intervention: Sham donation of 450 mL
Number of subjects: 21
Study 33030269 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proANP after 900 mL blood donation
Number of subjects: 21
Study 33030269 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proANP after 450 mL blood donation
Number of subjects: 21
Study 33030269 — intervention group
Group type: COMPARATOR
Intervention: Plasma proANP after sham donation of 900 mL
Number of subjects: 21
Study 33030269 — intervention group
Group type: COMPARATOR
Intervention: Plasma proANP after sham donation of 450 mL
Number of subjects: 21
Study 33030269 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume after 900 mL blood donation
Number of subjects: 21
Study 35409466 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention group with activity tracker (AG)
Number of subjects: 551
Study 35409466 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based or print-based intervention group (IG)
Number of subjects: 551
Study 35409466 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 551
Study 35143714 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD) with chlorhexidine
Number of subjects: 42
Study 35143714 — intervention group
Group type: COMPARATOR
Intervention: Quadrant-based scaling and root planing (Q-SRP)
Number of subjects: 42
Study 35143714 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth scaling and root planing (FM-SRP)
Number of subjects: 42
Study 34120401 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the Dental Trauma Guide (DTG)
Number of subjects: 21
Study 34120401 — intervention group
Group type: COMPARATOR
Intervention: Standard undergraduate curriculum without DTG access
Number of subjects: 21
Study 33064711 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg pregabalin
Number of subjects: 100
Study 33064711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33888251 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2890
Study 33888251 — intervention group
Group type: COMPARATOR
Intervention: Usual Care plus Microfinance (MF)
Number of subjects: 2890
Study 33888251 — intervention group
Group type: COMPARATOR
Intervention: Group Medical Visits (GMV)
Number of subjects: 2890
Study 33888251 — intervention group
Group type: COMPARATOR
Intervention: GMV integrated into MF (GMV‐MF)
Number of subjects: 2890
Study 32445322 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoplastic pelvic mask
Number of subjects: 35
Study 32445322 — intervention group
Group type: COMPARATOR
Intervention: Knee wedge
Number of subjects: 35
Study 33065953 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 40 U (20 U to frontalis and 20 U to glabellar complex)
Number of subjects: 391
Study 33065953 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 40 U
Number of subjects: 391
Study 33065953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 34032799 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Video Gaming (IVG) group, 12-week intervention, 2 x 1 hour sessions weekly
Number of subjects: 45
Study 34032799 — intervention group
Group type: COMPARATOR
Intervention: Conventional Multimodal (CM) group, 12-week intervention, 2 x 1 hour sessions weekly
Number of subjects: 45
Study 36482142 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistically appropriate printed decision aid
Number of subjects: 48
Study 36482142 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 48
Study 34115076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydraulic device and nanohydroxylapatite paste (Ostim) for sinus floor elevation
Number of subjects: 110
Study 36346729 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg infusion, once at the start of the study)
Number of subjects: 62
Study 36346729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 32282432 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous nitroglycerin (5 μg/kg in 0.5 ml)
Number of subjects: 113
Study 32282432 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.5 ml)
Number of subjects: 113
Study 36457044 — intervention group
Group type: EXPERIMENTAL
Intervention: InTSHA (Interactive Transition Support for Adolescents Living with HIV) mHealth intervention
Number of subjects: 21
Study 33483269 — intervention group
Group type: COMPARATOR
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 51
Study 33483269 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block (SAPB)
Number of subjects: 51
Study 33483269 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 51
Study 35019221 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide (290 μg/d)
Number of subjects: 659
Study 35019221 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 659
Study 33239245 — intervention group
Group type: EXPERIMENTAL
Intervention: Single low-dose ketamine infusion of 0.5 mg/kg
Number of subjects: 73
Study 35084613 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPAS program (experimental group)
Number of subjects: 2047
Study 35084613 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2047
Study 34767655 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE training
Number of subjects: 30
Study 34767655 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 32519588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue task
Number of subjects: 30
Study 32519588 — intervention group
Group type: COMPARATOR
Intervention: Watching a documentary (Control)
Number of subjects: 30
Study 36410832 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive e-learning intervention
Number of subjects: 275
Study 36410832 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adaptive e-learning intervention
Number of subjects: 275
Study 36410832 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 275
Study 34959813 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast Consumption (BC) - daily standardized breakfast consumption (energy content: 25% of resting metabolic rate) before 09:00
Number of subjects: 0
Study 34959813 — intervention group
Group type: COMPARATOR
Intervention: Breakfast Omission (BO) - no energy-providing nutrients consumed until 10:30
Number of subjects: 0
Study 32185990 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaoyang Xibi decoction (SYXBD)
Number of subjects: 66
Study 32185990 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 66